Sugi Predict

Sugi Predict / Targets / OGFRL1

OGFRL1

Opioid growth factor receptor-like protein 1 · Q5TC84 · OGFRL1 on Sugi Atlas →

16,682 patent compounds predicted against OGFRL1, 8,700 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL851990 SCHEMBL851990 1.00 20/20
SCHEMBL852051 SCHEMBL852051 1.00 20/20
SCHEMBL852052 SCHEMBL852052 1.00 20/20
SCHEMBL852086 SCHEMBL852086 1.00 20/20
SCHEMBL852087 SCHEMBL852087 1.00 20/20
SCHEMBL852111 SCHEMBL852111 1.00 20/20
SCHEMBL852112 SCHEMBL852112 1.00 20/20
SCHEMBL852143 SCHEMBL852143 1.00 20/20
SCHEMBL852144 SCHEMBL852144 1.00 20/20
SCHEMBL852163 SCHEMBL852163 1.00 20/20
SCHEMBL852164 SCHEMBL852164 1.00 20/20
SCHEMBL852165 SCHEMBL852165 1.00 20/20
SCHEMBL852166 SCHEMBL852166 1.00 20/20
SCHEMBL852201 SCHEMBL852201 1.00 20/20
SCHEMBL852202 SCHEMBL852202 1.00 20/20
SCHEMBL852222 SCHEMBL852222 1.00 20/20
SCHEMBL852223 SCHEMBL852223 1.00 20/20
SCHEMBL852256 SCHEMBL852256 1.00 20/20
SCHEMBL852257 SCHEMBL852257 1.00 20/20
SCHEMBL852262 SCHEMBL852262 1.00 20/20

Clinical trials — most relevant to OGFRL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Chronic Pain From Osteoarthritis PHASE4WITHDRAWN
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain PHASE4SUSPENDED
Topical Morphine for Analgesia in Patients With Skin Grafts PHASE3WITHDRAWN
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery PHASE2COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer PHASE1/PHASE2COMPLETED
Oxytocin for Oxidative Stress and Inflammation PHASE2COMPLETED
Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain PHASE2COMPLETED
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor PHASE1COMPLETED
Neuroimmune Effects of Opioid Administration PHASE1COMPLETED
First-in-man Imaging of a New PET Radiotracer for Oxytocin Receptors EARLY_PHASE1COMPLETED
Precision Medicine in Anesthesia nanWITHDRAWN
Affective Touch, Hedonia and Suicidal Behavior nanCOMPLETED
Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction nanUNKNOWN
Multicenter Perioperative Opioid Pharmacogenetic Study nanCOMPLETED
Cancer Pain Single Nucleotide Polymorphisms (SNPs) nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
A Study of Genetic Variation Influencing Pain and Response to Opioid Medications nanWITHDRAWN
Effect of Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients nanNOT_YET_RECRUITING
Patient Controlled Analgesia Pharmacogenetic Study nanCOMPLETED
Pharmacogenetic Morphine Spine Study nanCOMPLETED
Osteoprosis in Type 2 Diabetic Patients- a Cohort Study nanUNKNOWN
Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study nanCOMPLETED
Acute Kidney Injury After Cardiac Surgery nanCOMPLETED
Genetic Determinants of Opioids Analgesia nanCOMPLETED
Duration of Analgesia in Bier Block for Patients Undergoing Hand Surgery nanUNKNOWN
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a OGFRL1 binder may also engage these)

ProteinNameSimilarity
Q8VE52 — 1.000 Q8VE52 →
Q4KLH3 — 0.998 Q4KLH3 →
A2VCV0 — 0.994 A2VCV0 →
Q92833 — 0.988 Q92833 →
Q5PQX1 — 0.987 Q5PQX1 →
Q62315 — 0.987 Q62315 →
Q8CCG4 — 0.986 Q8CCG4 →
A0JP43 — 0.985 A0JP43 →
Q76N89 — 0.985 Q76N89 →
A5D794 — 0.985 A5D794 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.985 landscape →
Q8K4P8 — 0.985 Q8K4P8 →
Q9DAU9 — 0.984 Q9DAU9 →
TOR1AIP1 Torsin-1A-interacting protein 1 0.984 landscape →
Q8N4S0 — 0.984 Q8N4S0 →
Q9H2G9 — 0.984 Q9H2G9 →
TERF2 Telomeric repeat-binding factor 2 0.983 landscape →
O14607 — 0.983 O14607 →
Q99PG2 — 0.983 Q99PG2 →
Q8N7X0 — 0.983 Q8N7X0 →
Q93ZS1 — 0.983 Q93ZS1 →
Q6PFH3 — 0.983 Q6PFH3 →
Q6I6G8 — 0.983 Q6I6G8 →
Q62925 — 0.982 Q62925 →
Q3UMB5 — 0.982 Q3UMB5 →
A1A4J7 — 0.982 A1A4J7 →
A6QLD2 — 0.982 A6QLD2 →
Q9D3S3 — 0.982 Q9D3S3 →
Q5F363 — 0.982 Q5F363 →
Q8BMD7 — 0.982 Q8BMD7 →